Medicare Coverage Timeline After FDA Clearance: Why the Average Wait Is 5.7 Years

FDA authorisation is a gate, not a finish line. The number that makes this concrete comes from a Stanford Byers Center for Biodesign study published in JAMA Health Forum: among novel technologies that needed a new reimbursement pathway, the median time from FDA authorisation to at least nominal Medicare coverage was 5.7 years.

The same study found that of 64 devices and diagnostics authorised between 2016 and 2019 through PMA, De Novo or breakthrough-designated 510(k) routes, fewer than half had achieved nominal coverage by the end of 2022, and small companies waited longer than large ones.

If your financial model assumes revenue begins shortly after clearance, that is the number to argue with.

What "nominal coverage" means and why it is a generous bar

The study did not measure good coverage. It measured any coverage: an explicit national coverage determination, a local coverage determination from a Medicare Administrative Contractor, or implicit coverage inferred from the effective date of a new billing code.

That is a low bar deliberately, because it isolates the structural delay rather than the negotiation over rates. Real commercial coverage, at a rate that supports a business, typically arrives later still.

Where the 5.7 years actually goes

The delay is not one queue. It is three separate systems that run partly in sequence, and a stall in any of them holds up the rest.

Coding comes first. Before anyone can pay you, a claim has to be describable. That means an existing CPT or HCPCS code that genuinely matches your service, or a new one. New CPT codes run on the AMA CPT Editorial Panel's cycle, which meets three times a year, and a Category III code typically precedes a Category I code by several years. Our market access guide covers that assessment.

Coverage comes second, and it is not one decision. A national coverage determination applies everywhere but is slow and rare. Local coverage determinations are made by the contractors that administer Medicare regionally, which means the practical answer to "is it covered?" can be different in different states at the same time. Most novel devices travel the local route, contractor by contractor.

Payment comes third. A covered, coded service still needs a rate, and in the hospital outpatient setting that means an APC assignment and a payment status indicator. See our post on OPPS status indicator O1 for how that mechanism works for software.

The evidence expectation cuts across all three. FDA asks whether a device is safe and effective. CMS asks whether it is reasonable and necessary for the Medicare population, which skews older and sicker than most pivotal trial cohorts. Trials designed only for the FDA question routinely fail the CMS one, and the fix is another study.

Why small companies wait longer

The study's finding that smaller manufacturers wait longer is not mysterious. Coding applications, contractor engagement, evidence development and specialty-society support all take dedicated staff over multiple years. A large manufacturer runs that work in parallel with the submission. A small one starts it after clearance, because cash allowed nothing else, and then loses years it never budgeted for.

This is also why the gap compounds. Without coverage there is no revenue, without revenue there is no evidence budget, and without evidence there is no coverage.

What has changed since the study

Two things.

CMS finalised the Transitional Coverage for Emerging Technologies (TCET) pathway in 2024, intended to give a small number of FDA breakthrough-designated devices a structured route to national coverage with evidence development running alongside. It is capped in volume, which means it is a real option for a few products a year and not a general remedy.

Congress and CMS have both begun to address software specifically, through the proposed SaMS framework in the CY2027 OPPS rule and through the Health Tech Investment Act, which would set a statutory payment route with a protected window. Neither is settled, and neither retroactively helps a device authorised today.

How to shorten your own timeline

Start reimbursement work before clearance, not after. The coding question, the contractor landscape and the evidence gap can all be assessed while the submission is under review.

Design the pivotal trial to answer both questions. Include Medicare-representative patients and the outcomes a coverage reviewer will ask about. Adding them later costs a full study.

Map contractors, not just the country. Identify which Medicare Administrative Contractors cover your launch geographies and what they have said about comparable technologies.

Decide whether the US is genuinely the first market. Germany and France have named, dated statutory routes for software, as our post on international reimbursement pathways sets out. For some products the faster path to revenue is not the largest market.

Score markets on reimbursement, not just regulatory difficulty. MedTech Compass evaluates reimbursement friendliness and route alongside pathway complexity across 25+ markets, and DevicePath handles the classification and pathway triage that feeds it. Our market access guide and FDA pathways guide go deeper on each side.

The honest summary

5.7 years is a median, which means half of the technologies studied took longer, and 56 percent had not reached nominal coverage at all when the analysis closed. Treating clearance as the start of commercialisation, rather than the middle of it, is the single most useful correction most medtech plans can make.

Sources

1. Sexton ZA et al., Time From Authorization by the US Food and Drug Administration to Medicare Coverage for Novel Technologies, JAMA Health Forum, 2023: https://pmc.ncbi.nlm.nih.gov/articles/PMC10403784/ 2. Stanford Mussallem Center for Biodesign, summary of the study: https://med.stanford.edu/biodesign/our-impact/stories/stanford-researchers-study-the-timelines-from-fda-authorization-to-medicare-approval.html 3. CMS, Medicare coverage determination process: https://www.cms.gov/medicare/coverage/determination-process 4. Federal Register, Medicare Program; Transitional Coverage for Emerging Technologies: https://www.federalregister.gov/documents/2024/08/12/2024-17603/medicare-program-transitional-coverage-for-emerging-technologies 5. CMS, Hospital Outpatient Prospective Payment System: https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient

This article is general information, not legal or reimbursement advice. Coverage outcomes are product-specific and contractor-specific.